Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.2/5

OSE Immuno (OSE FP)

47
Analysis
Health CareFrance
OSE Immunotherapeutics SA is a biotechnology company based in France, developing immunotherapy products against invasive/metastatic late-stage cancers.
more
bullishOSE Immuno
05 Jun 2025 10:00Issuer-paid

OSE Immunotherapeutics — New UC biomarker underpins growth strategy

OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and...

Share
bullishOSE Immuno
03 Jun 2025 10:00Issuer-paid

OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential

OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...

Share
bullishOSE Immuno
03 Jun 2025 09:00Issuer-paid

OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential

OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...

Share
bullishOSE Immuno
22 May 2025 14:00Issuer-paid

OSE Immunotherapeutics — Strategic collaboration in mRNA technologies

OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop...

Share
bullishOSE Immuno
06 May 2025 16:00Issuer-paid

OSE Immunotherapeutics — Lusvertikimab impresses in extension period data

OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of...

Share
x